Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
31 Aug 2024
31 Aug 2024
Historique:
received:
10
06
2024
accepted:
20
08
2024
revised:
31
07
2024
medline:
1
9
2024
pubmed:
1
9
2024
entrez:
31
8
2024
Statut:
aheadofprint
Résumé
The kappa opioid receptor (KOR) and its endogenous agonist dynorphin have been implicated in multiple psychiatric conditions including psychotic disorders. We tested the hypotheses that kappa expression is elevated and associated with psychotic symptoms in schizophrenia. We measured kappa expression in unmedicated patients with schizophrenia (7 female, 6 male) and matched controls (7 female, 6 male) with positron emission tomography (PET). We also acquired a measurement of cumulative dopamine activity over the life span in the same subjects using neuromelanin sensitive MRI. We hypothesized that neuromelanin accumulation would be higher in patients than controls and that in patients there would be a positive association between KOR availability and neuromelanin accumulation. Fourteen patients and thirteen controls were enrolled. Whole brain dynamic PET imaging data using the KOR selective tracer [
Identifiants
pubmed: 39217267
doi: 10.1038/s41386-024-01975-3
pii: 10.1038/s41386-024-01975-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-02
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-02
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-02
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-0
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-0
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-0
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-02
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : 5R21MH125454-02
Informations de copyright
© 2024. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
Clark SD, Abi-Dargham A. The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence. Biol Psychiatry. 2019;86:502–11.
pubmed: 31376930
doi: 10.1016/j.biopsych.2019.05.012
Clark SD, et al. Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials. Neuropsychopharmacology. 2020;45:1860–9.
pubmed: 32516800
pmcid: 7608351
doi: 10.1038/s41386-020-0730-z
Watson SJ, et al. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects. Science. 1978;201:73–6.
pubmed: 351804
doi: 10.1126/science.351804
Emrich HM, et al. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiatr Neuropsychopharmakol. 1977;10:265–70.
pubmed: 30101
doi: 10.1055/s-0028-1094547
Berger PA, et al. The effects of naloxone in chronic schizophrenia. Am J Psychiatry. 1981;138:913–8.
pubmed: 6266259
doi: 10.1176/ajp.138.7.913
Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharm Exp Ther. 1988;244:1067–80.
Britt JP, McGehee DS. Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. J Neurosci. 2008;28:1672–81.
pubmed: 18272687
pmcid: 6671549
doi: 10.1523/JNEUROSCI.4275-07.2008
Howes OD, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776–86.
pubmed: 22474070
pmcid: 3730746
doi: 10.1001/archgenpsychiatry.2012.169
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549–62.
pubmed: 19325164
pmcid: 2669582
doi: 10.1093/schbul/sbp006
Laruelle M, ABi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999;13:358–78.
Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275:1593–9. p.
pubmed: 9054347
doi: 10.1126/science.275.5306.1593
Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28:309–69.
pubmed: 9858756
doi: 10.1016/S0165-0173(98)00019-8
Kegeles L, et al. Increased synaptic dopamine in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67:231–9.
pubmed: 20194823
doi: 10.1001/archgenpsychiatry.2010.10
Slifstein M, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72:316–24.
pubmed: 25651194
pmcid: 4768742
doi: 10.1001/jamapsychiatry.2014.2414
Naganawa M, et al. Evaluation of F-18-LY2459989 for imaging the kappa opioid receptor in humans. J Nucl Med. 2019;60:577.
Nabulsi NB, et al. Evaluation of the first F-18-labeled PET radiotracer F-18-LY2459989 for imaging kappa opioid receptor in humans. J Cereb Blood Flow Metab. 2019;39:89–89.
Cassidy CM, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci USA. 2019;116:5108–17.
pubmed: 30796187
pmcid: 6421437
doi: 10.1073/pnas.1807983116
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome scale (PANSS) for schizophrenia. Schiz Bull. 1987;13:261–76.
doi: 10.1093/schbul/13.2.261
Andreasen, NC. Scale for the assessment of negative symptoms/scale for the assessment of positive symptoms. Iowa City: University of Iowa Press; 1984.
Cai Z, et al. Fluorine-18-labeled antagonist for PET imaging of kappa opioid receptors. ACS Chem Neurosci. 2017;8:12–16.
pubmed: 27741398
doi: 10.1021/acschemneuro.6b00268
Mawlawi O, et al. Performance characteristics of a head immobilization device for PET imaging. J Nucl Med. 1999;40:281P–281P.
Abi-Dargham A, et al. Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112. J Psychopharmacol. 2012;26:794–805.
pubmed: 21768159
doi: 10.1177/0269881111409265
SPM Online Documentation 2021. https://www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf .
Chen X, et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn Reson Imaging. 2014;32:1301–6.
pubmed: 25086330
doi: 10.1016/j.mri.2014.07.003
Wengler K, et al. Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. Neuroimage. 2020;208:116457.
pubmed: 31841683
doi: 10.1016/j.neuroimage.2019.116457
Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238–45.
pubmed: 16254064
doi: 10.1093/schbul/sbj013
Ueno F, et al. Neuromelanin accumulation in patients with schizophrenia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;132:1205–13.
pubmed: 34718049
doi: 10.1016/j.neubiorev.2021.10.028
O’Brien CP, et al. Endogenous opioids in cerebrospinal fluid of opioid-dependent humans. Biol Psychiatry. 1988;24:649–62.
pubmed: 2844315
doi: 10.1016/0006-3223(88)90139-4
Shahkarami K, et al. Evaluation of dynorphin and kappa-opioid receptor level in the human blood lymphocytes and plasma: Possible role as a biomarker in severe opioid use disorder. Drug Alcohol Depend. 2019;205:107638.
pubmed: 31710992
doi: 10.1016/j.drugalcdep.2019.107638
Wengler K, et al. Generalizability and out-of-sample predictive ability of associations between neuromelanin-sensitive magnetic resonance imaging and psychosis in antipsychotic-free individuals. JAMA Psychiatry. 2024;81:198–208.
pubmed: 37938847
doi: 10.1001/jamapsychiatry.2023.4305
Krystal AD, et al. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating kappa-opioid antagonism as a treatment for anhedonia. Nat Med. 2020;26:760–8.
pubmed: 32231295
pmcid: 9949770
doi: 10.1038/s41591-020-0806-7
Schmidt ME, et al. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study. Neuropsychopharmacology. 2024;49:1437–47.
Harvey PO, et al. Functional neural substrates of self-reported physical anhedonia in non-clinical individuals and in patients with schizophrenia. J Psychiatr Res. 2010;44:707–16.
pubmed: 20116072
doi: 10.1016/j.jpsychires.2009.12.008
Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35:537–55.
pubmed: 20603146
doi: 10.1016/j.neubiorev.2010.06.006
First M, et al., Structured clinical interview for DSM-IV Axis I Disorders (SCID-I/P, Version 2.0). New York: Biometrics Research Dept., New York State Psychiatric Institute; 1995.
First M, et al., Structured clinical interview for DSM-5-research version (SCID-5 for DSM-5, research version, SCID-5-RV), ed. a.p. association. Arlington, VA; 2015.
Skumlien M, et al. The acute and non-acute effects of cannabis on reward processing: A systematic review. Neurosci Biobehav Rev. 2021;130:512–28.
pubmed: 34509513
doi: 10.1016/j.neubiorev.2021.09.008
Volkow ND, et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci USA. 2014;111:E3149–56.
pubmed: 25024177
pmcid: 4121778
doi: 10.1073/pnas.1411228111
Abplanalp SJ, et al. Understanding connections and boundaries between positive symptoms, negative symptoms, and role functioning among individuals with schizophrenia: a network psychometric approach. JAMA Psychiatry. 2022;79:1014–22.
pubmed: 35976655
pmcid: 9386606
doi: 10.1001/jamapsychiatry.2022.2386
Gard DE, et al. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93:253–60.
pubmed: 17490858
pmcid: 1986826
doi: 10.1016/j.schres.2007.03.008
Barch DM, Pagliaccio D, Luking K. Mechanisms underlying motivational deficits in psychopathology: similarities and differences in depression and schizophrenia. Curr Top Behav Neurosci. 2016;27:411–49.
pubmed: 26026289
doi: 10.1007/7854_2015_376
Krystal JH, et al. Mobilizing an institutional supportive response for healthcare workers and other staff in the context of COVID-19: the Yale experience. Gen Hospital Psychiatry. 2021;68:12–18.
doi: 10.1016/j.genhosppsych.2020.11.005
Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80:1–27.
pubmed: 9658025
doi: 10.1152/jn.1998.80.1.1
Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010;35:4–26.
pubmed: 19812543
doi: 10.1038/npp.2009.129
Gold JM, Waltz JA, Frank MJ. Effort cost computation in schizophrenia: a commentary on the recent literature. Biol Psychiatry. 2015;78:747–53.
pubmed: 26049208
pmcid: 4636936
doi: 10.1016/j.biopsych.2015.05.005
Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res. 2008;14:169–83.
pubmed: 19073424
pmcid: 3155128
doi: 10.1007/BF03033808
Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA. 1992;89:2046–50.
pubmed: 1347943
pmcid: 48593
doi: 10.1073/pnas.89.6.2046
Tejeda HA, Bonci A. Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders. Brain Res. 2019;1713:91–101.
pubmed: 30244022
doi: 10.1016/j.brainres.2018.09.023
Carlezon WA Jr., Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety. 2016;33:895–906.
pubmed: 27699938
pmcid: 5288841
doi: 10.1002/da.22500
Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006;59:1151–9.
pubmed: 16566899
doi: 10.1016/j.biopsych.2005.09.018
Innis RB, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.
pubmed: 17519979
doi: 10.1038/sj.jcbfm.9600493
Cunningham VJ, et al. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46–50.
pubmed: 19738632
doi: 10.1038/jcbfm.2009.190
Martinez D, et al. Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. Neuropsychopharmacology. 2019;44:1720–7.
pubmed: 31026862
pmcid: 6785004
doi: 10.1038/s41386-019-0398-4